JP2014223083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014223083A5 JP2014223083A5 JP2014155821A JP2014155821A JP2014223083A5 JP 2014223083 A5 JP2014223083 A5 JP 2014223083A5 JP 2014155821 A JP2014155821 A JP 2014155821A JP 2014155821 A JP2014155821 A JP 2014155821A JP 2014223083 A5 JP2014223083 A5 JP 2014223083A5
- Authority
- JP
- Japan
- Prior art keywords
- affinity reagent
- cancer
- seq
- antibody
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108010091175 Matriptase Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000003278 mimic effect Effects 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 claims 1
- 229930193936 anticarin Natural products 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000012642 immune effector Substances 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96383707P | 2007-08-07 | 2007-08-07 | |
| US60/963,837 | 2007-08-07 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519988A Division JP5864856B2 (ja) | 2007-08-07 | 2008-08-07 | マトリプターゼタンパク質及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014223083A JP2014223083A (ja) | 2014-12-04 |
| JP2014223083A5 true JP2014223083A5 (https=) | 2015-03-05 |
Family
ID=40239716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519988A Expired - Fee Related JP5864856B2 (ja) | 2007-08-07 | 2008-08-07 | マトリプターゼタンパク質及びその使用 |
| JP2014155821A Withdrawn JP2014223083A (ja) | 2007-08-07 | 2014-07-31 | マトリプターゼタンパク質及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010519988A Expired - Fee Related JP5864856B2 (ja) | 2007-08-07 | 2008-08-07 | マトリプターゼタンパク質及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8420091B2 (https=) |
| EP (1) | EP2185933B1 (https=) |
| JP (2) | JP5864856B2 (https=) |
| AU (1) | AU2008284271B2 (https=) |
| DK (1) | DK2185933T3 (https=) |
| ES (1) | ES2550754T3 (https=) |
| WO (1) | WO2009020645A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011063127A1 (en) | 2009-11-18 | 2011-05-26 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| US20120294800A1 (en) * | 2009-01-07 | 2012-11-22 | University Of Medicine And Dentistry Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| CN102341412B (zh) * | 2009-03-05 | 2018-01-05 | 梅达雷克斯有限责任公司 | 特异于cadm1 的全人抗体 |
| US9849192B2 (en) | 2009-11-18 | 2017-12-26 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies |
| EP2904015A4 (en) | 2012-10-02 | 2016-10-05 | Univ Rutgers | TARGETED RELEASE OF ANTIBODIES TO ACTIVATED MATRIPTASE-CONJUGATED TOXINS |
| KR20160079818A (ko) * | 2013-11-25 | 2016-07-06 | 옥스포드 바이오테라퓨틱스 리미티드 | 암 치료용 항-매트립타제 항체 |
| KR102441107B1 (ko) * | 2014-11-07 | 2022-09-13 | 후지쿠라 가세이 가부시키가이샤 | 데옥시하이푸신·신타제 유전자를 지표로서 사용하는 동맥 경화 및 암의 검출 방법 |
| CA3017958C (en) | 2016-03-18 | 2024-03-12 | Rutgers, The State University Of New Jersey | Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972616A (en) | 1998-02-20 | 1999-10-26 | The Board Of Trustees Of The University Of Arkansas | TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas |
| US7022821B1 (en) | 1998-02-20 | 2006-04-04 | O'brien Timothy J | Antibody kit for the detection of TADG-15 protein |
| EP1161266A4 (en) | 1999-03-12 | 2007-09-19 | Univ Georgetown | Matriptase, a serine protease and its applications |
| US7030231B1 (en) | 1999-09-30 | 2006-04-18 | Catalyst Biosciences, Inc. | Membrane type serine protease 1 (MT-SP1) and uses thereof |
| CA2388450C (en) * | 1999-10-20 | 2013-02-12 | The Board Of Trustees Of The University Of Arkansas | Tadg-15: an extracellular serine protease overexpressed in carcinomas |
| US6447978B1 (en) | 1999-12-03 | 2002-09-10 | Kodak Polychrome Graphics Llc | Imaging member containing heat switchable polymer and method of use |
| EP1252300B1 (en) | 2000-02-03 | 2011-01-19 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| US6903201B2 (en) | 2001-01-05 | 2005-06-07 | Curagen Corporation | Proteins and nucleic acids encoding same |
| WO2002072786A2 (en) | 2001-03-13 | 2002-09-19 | Corvas International, Inc. | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
| AU2002254357A1 (en) | 2001-03-22 | 2002-10-08 | Dendreon Corporation | Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon |
| CA2442089A1 (en) | 2001-03-27 | 2002-10-03 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon |
| US7112430B2 (en) | 2001-05-14 | 2006-09-26 | Dendreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| US7019019B2 (en) | 2002-12-23 | 2006-03-28 | Dendreon Corporation | Matriptase inhibitors and methods of use |
| CN1985489B (zh) | 2004-07-09 | 2012-05-09 | 艾利森电话股份有限公司 | 在多媒体通信系统中提供不同服务的方法和装置 |
| CA2592249C (en) | 2004-12-20 | 2014-07-29 | Amgen Fremont Inc. | Binding proteins specific for human matriptase |
| WO2006090389A2 (en) | 2005-02-24 | 2006-08-31 | Compugen Ltd. | Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof |
| EP1938104A2 (en) * | 2005-10-17 | 2008-07-02 | Institute for Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
-
2008
- 2008-08-07 AU AU2008284271A patent/AU2008284271B2/en not_active Ceased
- 2008-08-07 EP EP08795130.7A patent/EP2185933B1/en not_active Not-in-force
- 2008-08-07 JP JP2010519988A patent/JP5864856B2/ja not_active Expired - Fee Related
- 2008-08-07 DK DK08795130.7T patent/DK2185933T3/en active
- 2008-08-07 WO PCT/US2008/009512 patent/WO2009020645A2/en not_active Ceased
- 2008-08-07 ES ES08795130.7T patent/ES2550754T3/es active Active
-
2010
- 2010-02-07 US US12/701,566 patent/US8420091B2/en not_active Expired - Fee Related
-
2014
- 2014-07-31 JP JP2014155821A patent/JP2014223083A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014223083A5 (https=) | ||
| HRP20191609T1 (hr) | Protein | |
| CN110177806B (zh) | 与met结合的抗met抗体、双特异性抗原结合分子及其使用方法 | |
| MX2024013960A (es) | Anticuerpos anti-ox40 y metodos de uso | |
| JP2013506428A5 (https=) | ||
| ZA202101495B (en) | Chimeric antigen receptor | |
| JP2018052979A5 (https=) | ||
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| CY1122302T1 (el) | Νεα anti-cd38 αντισωματα για τη θεραπευτικη αγωγη καρκινου | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| SA519402358B1 (ar) | Ccr7 مترافقات عقار جسم مضاد لـ | |
| HRP20180507T1 (hr) | Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju | |
| MX2021006389A (es) | Anticuerpo cd3 y uso farmaceutico del mismo. | |
| EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
| JP2014240385A5 (https=) | ||
| HRP20231281T1 (hr) | Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom | |
| JP2020536109A5 (https=) | ||
| JP2018515474A5 (https=) | ||
| MX421450B (es) | Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19) | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2011509079A5 (https=) | ||
| EA201891066A1 (ru) | Антитела к ror1 | |
| JP2012121878A5 (https=) | ||
| JP2014039548A5 (https=) |